Screener
BridgeBio Pharma BBIO Reportable Segment — SG&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Other development programs | 6,760 | 11,430 |
| Other research programs | 16,916 | 18,007 |
| Total segment research and development | 126,636 | 111,431 |
| Selling, general and administrative | 163,896 | 106,365 |
| Restructuring, impairment, and related charges | — | 570 |
| Total operating costs and expenses | 300,471 | 221,005 |
| Loss from operations | (105,956) | (104,372) |
| Other income (expense), net: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's reportable segment — SG&A?
- BridgeBio Pharma (BBIO) reported reportable segment — SG&A of $163.9M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — SG&A changed year-over-year?
- BridgeBio Pharma's reportable segment — SG&A increased by 54.1% year-over-year, from $106.37M to $163.9M.
- What does reportable segment — SG&A mean?
- Covers the overhead costs associated with operating the segment, including marketing, sales force compensation, legal, and general corporate support. It reflects the operational scale and commercial infrastructure of the business.
Ask your AI about BridgeBio Pharma's reportable segment — sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude